Deloitte Unveils 2024 North America Technology Fast 500 Rankings
| TGTX Stock | USD 33.50 1.34 4.17% |
Slightly above 59% of all TG Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding TG Therapeutics suggests that some traders are interested. TG Therapeutics' investing sentiment can be driven by a variety of factors including economic data, TG Therapeutics' earnings reports, geopolitical events, and overall market trends.
TGTX |
Deloitte today released its North America Technology Fast 500, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences, fintech, and energy tech sectors, now in its 30th year.
Read at finance.yahoo.com
 |
TG Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards TG Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
TG Therapeutics Fundamental Analysis
We analyze TG Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TG Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TG Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
TG Therapeutics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
TG Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TG Therapeutics stock to make a market-neutral strategy. Peer analysis of TG Therapeutics could also be used in its relative valuation, which is a method of valuing TG Therapeutics by comparing valuation metrics with similar companies.
Peers
TG Therapeutics Related Equities
| XFOR | X4 Pharmaceuticals | 39.66 | ||||
| PDSB | PDS Biotechnology | 7.93 | ||||
| BTAI | BioXcel Therapeutics | 6.29 | ||||
| TERN | Terns Pharmaceuticals | 1.21 | ||||
| AKRO | Akero Therapeutics | 1.16 | ||||
| VKTX | Viking Therapeutics | 0.78 | ||||
| EXEL | Exelixis | 0.62 | ||||
| MDGL | Madrigal Pharmaceuticals | 0.00 | ||||
| HEPA | Hepion Pharmaceuticals | 1.00 |
Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.